All In Biotech

Free tool

FAERS Monitor: Ibrance

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212436 or its brand name (Ibrance, Palbociclib). Reports on generic versions are filed under their own applications.

Reports

95,562

Serious

50,805

53% of reports

Hospitalization

14,535

Death reported

10,701

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue15,790
  • white blood cell count decreased11,486
  • neoplasm progression10,612
  • nausea8,591
  • death8,004
  • neutropenia6,803
  • alopecia6,384
  • diarrhoea6,015
  • asthenia3,823
  • off label use3,677
  • pain3,509
  • decreased appetite3,508
  • malaise3,365
  • dyspnoea3,309
  • vomiting3,175

Reports by year received

View as table
YearReports
20125
20132
201414
20152,602
20165,940
20178,621
20189,067
201911,019
202012,869
202110,117
202212,585
202310,007
20246,069
20254,727
20261,918

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,958,597 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal10,61296.294.1696,179
white blood cell count decreasedSignal11,48626.025.5247,772
neutropeniaSignal6,80311.511.362,606
alopeciaSignal6,3847.47.234,269
fatigueSignal15,7904.54.544,270
decreased appetiteSignal3,5083.43.35,788
nauseaSignal8,5912.42.47,241
astheniaSignal3,8232.32.22,676
diarrhoeaSignal6,0152.12.03,356
deathSignal8,0042.12.04,475
malaise3,3651.71.6969
vomiting3,1751.51.4519
dyspnoea3,3091.31.2218
pain3,5091.31.2191
off label use3,6770.90.924

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.